Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

(“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in 3D human tissue models, has reached an agreement to sell its FXR program, including the lead asset FXR314, to ...

(“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly ...